Clinical Trial Update: Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors [Phase 1]

View source ↗

Summary

A Phase 1 study of the Factor VIIa variant BAY86-6150 (B0189) in adults with Hemophilia A or Hemophilia B (with or without inhibitors) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• BAY86-6150 (BAY86-6150)

Snippet

Sponsor: Bayer | Conditions: Hemophilia A, Hemophilia B | Phase 1 | Status: COMPLETED